|
|
Article: OTHER NEWS TO NOTE.
- Article from:
- BIOWORLD Today
- Article date:
- February 8, 2005
CopyrightCOPYRIGHT 2005 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Affectis Pharmaceuticals AG, of Munich, Germany, signed a collaboration agreement with Tokyo-based Mitsubishi Pharma Corp. to develop therapeutics for affective disorders. Under terms of the agreement, Affectis will apply its target validation technology and exclusive animal models for the validation of Mitsubishi's gene targets involved in depression and anxiety.
Atugen AG, of Berlin, and Asinex Ltd., of Moscow, announced a long-term drug discovery and development collaboration for a protein kinase target during the 3rd annual BioPartnering North America conference in Vancouver, British Columbia. Atugen said it will contribute work in target discovery ...